# Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

> **NCT03766867** · PHASE2 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 80 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** Vortioxetine infusion 25 mg
- **DRUG:** Vortioxetine tablets 10 mg/day
- **DRUG:** Placebo infusion
- **DRUG:** Placebo tablets

## Key facts

- **NCT ID:** NCT03766867
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-12-03
- **Primary completion:** 2019-07-31
- **Final completion:** 2019-08-28
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2019-08-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03766867

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03766867, "Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03766867. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*